Vericel (VCEL) is a commercial-stage biopharma company that focuses on sports medicine and severe burn care therapies. President and CEO, Nick Colangelo discusses VCEL as it expects an accelerated commercial launch for arthroscopic Maci. he notes that VCEL anticipates an accelerated potential commercial launch of arthroscopic Maci in 2024. He then goes over how VCEL announced FDA approval of Nexobird, U.S. commercial availability expected in 2Q23. Tune in to find out more about the stock market today.
20 Jan 2023
Trading 360
04 May 2023
Market On Close
26 May 2023
The Watch List
17 May 2023
Trading 360
29 Mar 2023
Morning Trade Live
25 May 2023
Market On Close
03 May 2023